Michallet, Mauricette
el Cheikh, Jean
Herbrecht, Raoul
Yakoub-Agha, Ibrahim
Caillot, Denis
Gangneux, Jean-Pierre
Funding for this research was provided by:
Astellas Pharma
Article History
Received: 5 November 2020
Accepted: 28 February 2022
First Online: 9 April 2022
Change Date: 22 April 2022
Change Type: Update
Change Details: In the original publication an author's family and given name has been incorrectly tagged. The article has been updated to include it
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki and with Good Epidemiological Practices. Approvals from national review boards (Comité Consultatif sur le Traitement de l’Information en matière de Recherche dans le domaine de la Santé and Commission Nationale de l’Informatique et des Libertés) were obtained. Patients hospitalized in participating units were required to provide written informed consent prior to inclusion in the study.
: Not applicable.
: Mauricette Michallet has been a consultant to Astellas, MSD, and Pfizer. Raoul Herbrecht has been a consultant and speaker to Pfizer and Gilead, respectively. Ibrahim Yakoub-Agha has been a consultant to Astellas Pharma and MSD. Jean El Cheikh declares no conflict of interest. Denis Caillot has been a consultant to Astellas Pharma and MSD. Jean-Pierre Gangneux has been a consultant to Astellas Pharma, Gilead, Merck, and Pfizer.